Eukaryotic ADCY7 catalyzes the production of c-di-AMP to activate the NLRP3 inflammasome

Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is not clear. We found that there is a second signal downstream of TLR9 that induces NLRP3 inflammasome activation. Through screening, adenylate c...

Full description

Saved in:
Bibliographic Details
Published inNature chemical biology Vol. 21; no. 8; pp. 1283 - 1291
Main Authors Liu, Qiannv, Tang, Zhiheng, Qian, Yan, Wang, Chunlei, Kong, Chun, Li, Mengqian, Geng, Xiangyang, Zhang, Yan, Cheng, Xiangyun, Ren, Chao, Wang, Kai, Bai, Lin, Wang, Lin, Jiang, Dong, Wang, Shuo, Liu, Xiaoyun, Xia, Pengyan
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.08.2025
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is not clear. We found that there is a second signal downstream of TLR9 that induces NLRP3 inflammasome activation. Through screening, adenylate cyclase 7 (ADCY7) was found to be an essential regulator of this process. In cells with Adcy7 deficiency, TLR9 agonists were no longer able to activate the NLRP3 inflammasome. ADCY7 not only catalyzes the generation of cyclic adenosine monophosphate (cAMP) but also catalyzes the synthesis of its dimeric form (c-di-AMP). Moreover, c-di-AMP promotes assembly and maturation of the inflammasome by directly binding to NLRP3. Cells with Adcy7 deletion or mutations impacting enzymatic activity cannot produce c-di-AMP. The survival of Adcy7 -deficient mice in acute liver injury was also improved. In summary, we found that ADCY7 is required for NLRP3 inflammasome activation downstream of TLR9 by catalyzing the generation of c-di-AMP, which may serve as a target for controlling inflammatory responses in sterile infections. Cyclic dimeric adenosine monophosphate is found to be a second messenger in eukaryotic cells that is generated by adenylate cyclase 7 and connects Toll-like receptor 9 stimulation to nucleotide-binding domain, leucine-rich repeat protein 3 inflammasome activation.
AbstractList Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is not clear. We found that there is a second signal downstream of TLR9 that induces NLRP3 inflammasome activation. Through screening, adenylate cyclase 7 (ADCY7) was found to be an essential regulator of this process. In cells with Adcy7 deficiency, TLR9 agonists were no longer able to activate the NLRP3 inflammasome. ADCY7 not only catalyzes the generation of cyclic adenosine monophosphate (cAMP) but also catalyzes the synthesis of its dimeric form (c-di-AMP). Moreover, c-di-AMP promotes assembly and maturation of the inflammasome by directly binding to NLRP3. Cells with Adcy7 deletion or mutations impacting enzymatic activity cannot produce c-di-AMP. The survival of Adcy7 -deficient mice in acute liver injury was also improved. In summary, we found that ADCY7 is required for NLRP3 inflammasome activation downstream of TLR9 by catalyzing the generation of c-di-AMP, which may serve as a target for controlling inflammatory responses in sterile infections. Cyclic dimeric adenosine monophosphate is found to be a second messenger in eukaryotic cells that is generated by adenylate cyclase 7 and connects Toll-like receptor 9 stimulation to nucleotide-binding domain, leucine-rich repeat protein 3 inflammasome activation.
Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is not clear. We found that there is a second signal downstream of TLR9 that induces NLRP3 inflammasome activation. Through screening, adenylate cyclase 7 (ADCY7) was found to be an essential regulator of this process. In cells with Adcy7 deficiency, TLR9 agonists were no longer able to activate the NLRP3 inflammasome. ADCY7 not only catalyzes the generation of cyclic adenosine monophosphate (cAMP) but also catalyzes the synthesis of its dimeric form (c-di-AMP). Moreover, c-di-AMP promotes assembly and maturation of the inflammasome by directly binding to NLRP3. Cells with Adcy7 deletion or mutations impacting enzymatic activity cannot produce c-di-AMP. The survival of Adcy7-deficient mice in acute liver injury was also improved. In summary, we found that ADCY7 is required for NLRP3 inflammasome activation downstream of TLR9 by catalyzing the generation of c-di-AMP, which may serve as a target for controlling inflammatory responses in sterile infections.Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is not clear. We found that there is a second signal downstream of TLR9 that induces NLRP3 inflammasome activation. Through screening, adenylate cyclase 7 (ADCY7) was found to be an essential regulator of this process. In cells with Adcy7 deficiency, TLR9 agonists were no longer able to activate the NLRP3 inflammasome. ADCY7 not only catalyzes the generation of cyclic adenosine monophosphate (cAMP) but also catalyzes the synthesis of its dimeric form (c-di-AMP). Moreover, c-di-AMP promotes assembly and maturation of the inflammasome by directly binding to NLRP3. Cells with Adcy7 deletion or mutations impacting enzymatic activity cannot produce c-di-AMP. The survival of Adcy7-deficient mice in acute liver injury was also improved. In summary, we found that ADCY7 is required for NLRP3 inflammasome activation downstream of TLR9 by catalyzing the generation of c-di-AMP, which may serve as a target for controlling inflammatory responses in sterile infections.
Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is not clear. We found that there is a second signal downstream of TLR9 that induces NLRP3 inflammasome activation. Through screening, adenylate cyclase 7 (ADCY7) was found to be an essential regulator of this process. In cells with Adcy7 deficiency, TLR9 agonists were no longer able to activate the NLRP3 inflammasome. ADCY7 not only catalyzes the generation of cyclic adenosine monophosphate (cAMP) but also catalyzes the synthesis of its dimeric form (c-di-AMP). Moreover, c-di-AMP promotes assembly and maturation of the inflammasome by directly binding to NLRP3. Cells with Adcy7 deletion or mutations impacting enzymatic activity cannot produce c-di-AMP. The survival of Adcy7-deficient mice in acute liver injury was also improved. In summary, we found that ADCY7 is required for NLRP3 inflammasome activation downstream of TLR9 by catalyzing the generation of c-di-AMP, which may serve as a target for controlling inflammatory responses in sterile infections.
Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is not clear. We found that there is a second signal downstream of TLR9 that induces NLRP3 inflammasome activation. Through screening, adenylate cyclase 7 (ADCY7) was found to be an essential regulator of this process. In cells with Adcy7 deficiency, TLR9 agonists were no longer able to activate the NLRP3 inflammasome. ADCY7 not only catalyzes the generation of cyclic adenosine monophosphate (cAMP) but also catalyzes the synthesis of its dimeric form (c-di-AMP). Moreover, c-di-AMP promotes assembly and maturation of the inflammasome by directly binding to NLRP3. Cells with Adcy7 deletion or mutations impacting enzymatic activity cannot produce c-di-AMP. The survival of Adcy7-deficient mice in acute liver injury was also improved. In summary, we found that ADCY7 is required for NLRP3 inflammasome activation downstream of TLR9 by catalyzing the generation of c-di-AMP, which may serve as a target for controlling inflammatory responses in sterile infections.Cyclic dimeric adenosine monophosphate is found to be a second messenger in eukaryotic cells that is generated by adenylate cyclase 7 and connects Toll-like receptor 9 stimulation to nucleotide-binding domain, leucine-rich repeat protein 3 inflammasome activation.
Author Wang, Shuo
Bai, Lin
Qian, Yan
Kong, Chun
Ren, Chao
Liu, Xiaoyun
Geng, Xiangyang
Liu, Qiannv
Cheng, Xiangyun
Xia, Pengyan
Wang, Chunlei
Jiang, Dong
Li, Mengqian
Wang, Lin
Zhang, Yan
Wang, Kai
Tang, Zhiheng
Author_xml – sequence: 1
  givenname: Qiannv
  surname: Liu
  fullname: Liu, Qiannv
  organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University
– sequence: 2
  givenname: Zhiheng
  surname: Tang
  fullname: Tang, Zhiheng
  organization: NHC Key Laboratory of Medical Immunology, Peking University, Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University
– sequence: 3
  givenname: Yan
  surname: Qian
  fullname: Qian, Yan
  organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University
– sequence: 4
  givenname: Chunlei
  surname: Wang
  fullname: Wang, Chunlei
  organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University
– sequence: 5
  givenname: Chun
  surname: Kong
  fullname: Kong, Chun
  organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University
– sequence: 6
  givenname: Mengqian
  surname: Li
  fullname: Li, Mengqian
  organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University
– sequence: 7
  givenname: Xiangyang
  surname: Geng
  fullname: Geng, Xiangyang
  organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University
– sequence: 8
  givenname: Yan
  surname: Zhang
  fullname: Zhang, Yan
  organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University
– sequence: 9
  givenname: Xiangyun
  surname: Cheng
  fullname: Cheng, Xiangyun
  organization: Department of Sports Medicine, Peking University Third Hospital, Beijing Key Laboratory of Sports Injuries, Institute of Sports Medicine of Peking University
– sequence: 10
  givenname: Chao
  surname: Ren
  fullname: Ren, Chao
  organization: Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University
– sequence: 11
  givenname: Kai
  surname: Wang
  fullname: Wang, Kai
  organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University
– sequence: 12
  givenname: Lin
  surname: Bai
  fullname: Bai, Lin
  organization: Department of Biophysics, School of Basic Medical Sciences, Peking University
– sequence: 13
  givenname: Lin
  orcidid: 0000-0003-1555-9985
  surname: Wang
  fullname: Wang, Lin
  organization: Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University
– sequence: 14
  givenname: Dong
  surname: Jiang
  fullname: Jiang, Dong
  organization: Department of Sports Medicine, Peking University Third Hospital, Beijing Key Laboratory of Sports Injuries, Institute of Sports Medicine of Peking University
– sequence: 15
  givenname: Shuo
  orcidid: 0000-0002-5383-3386
  surname: Wang
  fullname: Wang, Shuo
  email: wangshuo@im.ac.cn
  organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences
– sequence: 16
  givenname: Xiaoyun
  orcidid: 0000-0001-7083-5263
  surname: Liu
  fullname: Liu, Xiaoyun
  email: xiaoyun.liu@bjmu.edu.cn
  organization: NHC Key Laboratory of Medical Immunology, Peking University, Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University, Department of Infectious Diseases, Peking University Third Hospital
– sequence: 17
  givenname: Pengyan
  orcidid: 0000-0001-7959-5796
  surname: Xia
  fullname: Xia, Pengyan
  email: xiap@pku.edu.cn
  organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University, PUHSC Primary Immunodeficiency Research Center, Peking University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40419769$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtPxCAUhYnR-Bj9Ay4MiRs3KBcKtMvJ-EzGR4wLXRGGglbboqU1GX-96PhIXJi74IZ8h3u4ZwMtt6F1CG0D3QfK84OYgcgLQpkgFAooyHwJrYMQjGSZLJZ_ekHX0EaMj5RyKSFfRWsZzaBQslhHt0fDk-nmoa8sHh9O7hS2pjf1_M1F3D84_NyFcrB9FVocPLakrMj4_Ar3AZt0-2p694ldTK-vOK5aX5umMTE0bhOteFNHt_V1jtDN8dHN5JRML0_OJuMpsZzlPQGfyZnMuS-EUmCk51Lk3JQgvfOqKFnJS5uDZGYG4HOmqOV8ZgRVyklT8hHaWzybjL4MLva6qaJ1dW1aF4aoOYOPUunvI7T7B30MQ9cmc4niGQAVjCVq54saZo0r9XNXNWlB-ntlCWALwHYhxs75HwSo_shFL3LRKRf9mYueJxFfiGKC23vX_c7-R_UOTVONzA
Cites_doi 10.1038/s41590-021-00886-5
10.1111/j.1471-4159.1993.tb05852.x
10.1007/s00125-014-3437-z
10.1016/j.immuni.2017.06.020
10.1038/s41580-020-0244-x
10.1128/mBio.00018-13
10.3389/fimmu.2023.1151185
10.1016/j.tim.2017.09.003
10.1016/j.immuni.2022.10.021
10.1016/S0165-6147(99)01307-3
10.1039/C2CS35206K
10.1016/j.cell.2021.09.019
10.1038/s41564-020-0777-y
10.1021/cr300011s
10.1038/s41589-024-01569-6
10.1146/annurev-micro-032521-024017
10.1007/112_2020_55
10.4049/jimmunol.0901363
10.1159/000166277
10.7554/eLife.99939.3
10.1146/annurev-pathmechdis-032521-102529
10.1097/00000658-197511000-00012
10.1038/nature11588
10.1016/j.coph.2018.05.012
10.1074/jbc.M803281200
10.1016/j.cell.2023.05.038
10.1021/acs.jmedchem.9b01062
10.1016/j.addr.2008.12.008
10.1146/annurev-immunol-081022-021207
10.1038/embor.2013.132
10.1016/j.immuni.2018.04.032
10.1038/s41577-019-0165-0
10.2147/JIR.S464838
10.3389/fonc.2022.829212
10.1038/nri3452
10.1038/374546a0
10.1038/s41423-022-00922-w
10.1146/annurev-immunol-032713-120156
10.1038/nature08780
10.1038/s41423-024-01221-2
10.1124/pr.116.013078
10.1186/s13045-024-01524-x
10.1186/s12987-022-00322-2
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer Nature America, Inc. 2025 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
The Author(s), under exclusive licence to Springer Nature America, Inc. 2025
Copyright_xml – notice: The Author(s), under exclusive licence to Springer Nature America, Inc. 2025 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
– notice: The Author(s), under exclusive licence to Springer Nature America, Inc. 2025
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7QR
7TK
7TM
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
RC3
7X8
DOI 10.1038/s41589-025-01919-y
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Virology and AIDS Abstracts
Technology Research Database
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
Genetics Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Virology and AIDS Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
EISSN 1552-4469
EndPage 1291
ExternalDocumentID 40419769
10_1038_s41589_025_01919_y
Genre Journal Article
GrantInformation_xml – fundername: the National Key R&D Program of China (2021YFA1300202, 2022YFC2302900 and 2022YFA1304500), Strategic Priority Research Programs of the Chinese Academy of Sciences (XDB29020000), Key Research Program of Frontier Sciences of Chinese Academy of Sciences (ZDBS-LY-SM025), CAS Project for Young Scientists in Basic Research (YSBR-010)
– fundername: Natural Science Foundation of Beijing Municipality (Beijing Natural Science Foundation)
  grantid: JG23028
  funderid: https://doi.org/10.13039/501100004826
– fundername: Youth Innovation Promotion Association of the Chinese Academy of Sciences (Youth Innovation Promotion Association CAS)
  funderid: https://doi.org/10.13039/501100004739
– fundername: National Natural Science Foundation of China (National Science Foundation of China)
  grantid: 92369104, 82271790, 92169113, 22174003; 92369104; 92369104; 92369104; 82271790; 82271790; 82271790; 92369104; 92169113; 82271790; 82271790; 82271790; 82271790; 92369104; 92369104; 92369104; 92169113
  funderid: https://doi.org/10.13039/501100001809
– fundername: Fok Ying Tung Education Foundation (FYTEF)
  funderid: https://doi.org/10.13039/501100010261
– fundername: Natural Science Foundation of Beijing Municipality (Beijing Natural Science Foundation)
  grantid: JG23028
– fundername: National Natural Science Foundation of China (National Science Foundation of China)
  grantid: 92369104
– fundername: National Natural Science Foundation of China (National Science Foundation of China)
  grantid: 92369104, 82271790, 92169113, 22174003
– fundername: National Natural Science Foundation of China (National Science Foundation of China)
  grantid: 92169113
– fundername: National Natural Science Foundation of China (National Science Foundation of China)
  grantid: 82271790
GroupedDBID ---
0R~
123
29M
39C
4.4
53G
70F
7X7
88E
88I
8AO
8FE
8FG
8FH
8FI
8FJ
8R4
8R5
AARCD
AAYZH
ABAWZ
ABDBF
ABFSG
ABJCF
ABJNI
ABLJU
ABUWG
ACBWK
ACGFS
ACGOD
ACIWK
ACPRK
ACSTC
ACUHS
ADBBV
ADXHL
AENEX
AEUYN
AEZWR
AFANA
AFBBN
AFHIU
AFKRA
AFRAH
AFSHS
AGAYW
AHBCP
AHMBA
AHOSX
AHSBF
AHWEU
AIBTJ
AIXLP
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALPWD
ARMCB
ASPBG
ATHPR
AVWKF
AXYYD
AZFZN
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
BKKNO
BKSAR
BPHCQ
BVXVI
CCPQU
CS3
CZ9
D1I
DB5
DU5
DWQXO
EBS
EE.
EJD
EMOBN
ESX
EXGXG
F5P
FEDTE
FQGFK
FSGXE
FYUFA
GNUQQ
HCIFZ
HMCUK
HVGLF
HZ~
KB.
KC.
LK5
LK8
M1P
M2P
M7P
M7R
NACWA
NFIDA
NNMJJ
O9-
ODYON
P2P
PCBAR
PDBOC
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
Q2X
RNT
RNTTT
SHXYY
SIXXV
SJN
SNYQT
SOJ
SV3
TAOOD
TBHMF
TDRGL
TSG
TUS
UKHRP
~8M
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7QR
7TK
7TM
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
RC3
7X8
ID FETCH-LOGICAL-c328t-1f46b683f95771a6f36583ad16fef79d2d3dc8162ab11f8270c33ba5077e6ad3
ISSN 1552-4450
1552-4469
IngestDate Wed Jul 02 02:53:39 EDT 2025
Sat Aug 23 13:27:10 EDT 2025
Mon Aug 04 01:30:42 EDT 2025
Thu Aug 07 05:34:10 EDT 2025
Tue Jul 29 01:10:27 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c328t-1f46b683f95771a6f36583ad16fef79d2d3dc8162ab11f8270c33ba5077e6ad3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-1555-9985
0000-0001-7083-5263
0000-0002-5383-3386
0000-0001-7959-5796
PMID 40419769
PQID 3234110522
PQPubID 29034
PageCount 9
ParticipantIDs proquest_miscellaneous_3212121700
proquest_journals_3234110522
pubmed_primary_40419769
crossref_primary_10_1038_s41589_025_01919_y
springer_journals_10_1038_s41589_025_01919_y
PublicationCentury 2000
PublicationDate 20250800
PublicationDateYYYYMMDD 2025-08-01
PublicationDate_xml – month: 8
  year: 2025
  text: 20250800
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: United States
– name: Cambridge
PublicationTitle Nature chemical biology
PublicationTitleAbbrev Nat Chem Biol
PublicationTitleAlternate Nat Chem Biol
PublicationYear 2025
Publisher Nature Publishing Group US
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group US
– name: Nature Publishing Group
References A Di (1919_CR39) 2018; 49
W Gu (1919_CR7) 2024; 17
JR Barker (1919_CR29) 2013; 4
KP Hopfner (1919_CR41) 2020; 21
A Akbal (1919_CR37) 2022; 19
W Li (1919_CR45) 2024; 20
WF Simonds (1919_CR23) 1999; 20
Q Liu (1919_CR43) 2024; 21
J Sanchez-Collado (1919_CR17) 2021; 179
H Dou (1919_CR20) 2015; 58
LI Jiang (1919_CR16) 2008; 283
KC Lam (1919_CR30) 2021; 184
A Millman (1919_CR42) 2020; 5
J Wu (1919_CR33) 2014; 32
KV Swanson (1919_CR35) 2019; 19
AM Krieg (1919_CR10) 1995; 374
JM Blander (1919_CR34) 2018; 41
B Novotná (1919_CR32) 2019; 62
ML Steer (1919_CR15) 1975; 182
GS Lee (1919_CR25) 2012; 492
CW Dessauer (1919_CR22) 2017; 69
BI Herrmann (1919_CR6) 2023; 77
FG Bauernfeind (1919_CR8) 2009; 183
R Sadana (1919_CR21) 2009; 17
Q Zhang (1919_CR13) 2010; 464
KSG de Sá (1919_CR5) 2023; 14
E Latz (1919_CR4) 2013; 13
AA Abdul-Sater (1919_CR26) 2013; 14
R Guo (1919_CR14) 2022; 12
Y Qian (1919_CR44) 2025; 13
K Devasani (1919_CR18) 2022; 19
M de Carvalho Ribeiro (1919_CR2) 2022; 17
NA Schmacke (1919_CR38) 2022; 55
P Clivio (1919_CR40) 2013; 113
J Fu (1919_CR1) 2023; 41
AB Imaeda (1919_CR12) 2009; 119
FM Commichau (1919_CR27) 2018; 26
Y Li (1919_CR31) 2023; 186
D Kalia (1919_CR28) 2013; 42
Z Xia (1919_CR19) 1993; 60
H Zhang (1919_CR24) 2024; 17
J Vollmer (1919_CR11) 2009; 61
BR Sharma (1919_CR3) 2021; 22
X Zheng (1919_CR9) 2023; 14
F Di Virgilio (1919_CR36) 2017; 47
References_xml – volume: 22
  start-page: 550
  year: 2021
  ident: 1919_CR3
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-021-00886-5
– volume: 60
  start-page: 305
  year: 1993
  ident: 1919_CR19
  publication-title: J. Neurochem.
  doi: 10.1111/j.1471-4159.1993.tb05852.x
– volume: 58
  start-page: 324
  year: 2015
  ident: 1919_CR20
  publication-title: Diabetologia
  doi: 10.1007/s00125-014-3437-z
– volume: 47
  start-page: 15
  year: 2017
  ident: 1919_CR36
  publication-title: Immunity
  doi: 10.1016/j.immuni.2017.06.020
– volume: 21
  start-page: 501
  year: 2020
  ident: 1919_CR41
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/s41580-020-0244-x
– volume: 4
  start-page: e00018-13
  year: 2013
  ident: 1919_CR29
  publication-title: mBio
  doi: 10.1128/mBio.00018-13
– volume: 14
  start-page: 1151185
  year: 2023
  ident: 1919_CR9
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2023.1151185
– volume: 26
  start-page: 175
  year: 2018
  ident: 1919_CR27
  publication-title: Trends Microbiol.
  doi: 10.1016/j.tim.2017.09.003
– volume: 55
  start-page: 2271
  year: 2022
  ident: 1919_CR38
  publication-title: Immunity
  doi: 10.1016/j.immuni.2022.10.021
– volume: 20
  start-page: 66
  year: 1999
  ident: 1919_CR23
  publication-title: Trends Pharmacol. Sci.
  doi: 10.1016/S0165-6147(99)01307-3
– volume: 42
  start-page: 305
  year: 2013
  ident: 1919_CR28
  publication-title: Chem. Soc. Rev.
  doi: 10.1039/C2CS35206K
– volume: 184
  start-page: 5338
  year: 2021
  ident: 1919_CR30
  publication-title: Cell.
  doi: 10.1016/j.cell.2021.09.019
– volume: 5
  start-page: 1608
  year: 2020
  ident: 1919_CR42
  publication-title: Nat. Microbiol.
  doi: 10.1038/s41564-020-0777-y
– volume: 113
  start-page: 7354
  year: 2013
  ident: 1919_CR40
  publication-title: Chem. Rev.
  doi: 10.1021/cr300011s
– volume: 20
  start-page: 1434
  year: 2024
  ident: 1919_CR45
  publication-title: Nat. Chem. Biol.
  doi: 10.1038/s41589-024-01569-6
– volume: 77
  start-page: 451
  year: 2023
  ident: 1919_CR6
  publication-title: Annu. Rev. Microbiol.
  doi: 10.1146/annurev-micro-032521-024017
– volume: 179
  start-page: 73
  year: 2021
  ident: 1919_CR17
  publication-title: Rev. Physiol. Biochem. Pharmacol.
  doi: 10.1007/112_2020_55
– volume: 183
  start-page: 787
  year: 2009
  ident: 1919_CR8
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0901363
– volume: 17
  start-page: 5
  year: 2009
  ident: 1919_CR21
  publication-title: Neurosignals
  doi: 10.1159/000166277
– volume: 13
  start-page: RP99939
  year: 2025
  ident: 1919_CR44
  publication-title: eLife
  doi: 10.7554/eLife.99939.3
– volume: 17
  start-page: 345
  year: 2022
  ident: 1919_CR2
  publication-title: Annu. Rev. Pathol.
  doi: 10.1146/annurev-pathmechdis-032521-102529
– volume: 182
  start-page: 603
  year: 1975
  ident: 1919_CR15
  publication-title: Ann. Surg.
  doi: 10.1097/00000658-197511000-00012
– volume: 492
  start-page: 123
  year: 2012
  ident: 1919_CR25
  publication-title: Nature
  doi: 10.1038/nature11588
– volume: 41
  start-page: 128
  year: 2018
  ident: 1919_CR34
  publication-title: Curr. Opin. Pharmacol.
  doi: 10.1016/j.coph.2018.05.012
– volume: 119
  start-page: 305
  year: 2009
  ident: 1919_CR12
  publication-title: J. Clin. Invest.
– volume: 283
  start-page: 23429
  year: 2008
  ident: 1919_CR16
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M803281200
– volume: 186
  start-page: 3261
  year: 2023
  ident: 1919_CR31
  publication-title: Cell.
  doi: 10.1016/j.cell.2023.05.038
– volume: 62
  start-page: 10676
  year: 2019
  ident: 1919_CR32
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.9b01062
– volume: 61
  start-page: 195
  year: 2009
  ident: 1919_CR11
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2008.12.008
– volume: 41
  start-page: 301
  year: 2023
  ident: 1919_CR1
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev-immunol-081022-021207
– volume: 14
  start-page: 900
  year: 2013
  ident: 1919_CR26
  publication-title: EMBO Rep.
  doi: 10.1038/embor.2013.132
– volume: 49
  start-page: 56
  year: 2018
  ident: 1919_CR39
  publication-title: Immunity
  doi: 10.1016/j.immuni.2018.04.032
– volume: 19
  start-page: 477
  year: 2019
  ident: 1919_CR35
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-019-0165-0
– volume: 17
  start-page: 3801
  year: 2024
  ident: 1919_CR7
  publication-title: J. Inflamm. Res.
  doi: 10.2147/JIR.S464838
– volume: 12
  start-page: 829212
  year: 2022
  ident: 1919_CR14
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.829212
– volume: 13
  start-page: 397
  year: 2013
  ident: 1919_CR4
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3452
– volume: 374
  start-page: 546
  year: 1995
  ident: 1919_CR10
  publication-title: Nature
  doi: 10.1038/374546a0
– volume: 19
  start-page: 1201
  year: 2022
  ident: 1919_CR37
  publication-title: Cell. Mol. Immunol.
  doi: 10.1038/s41423-022-00922-w
– volume: 32
  start-page: 461
  year: 2014
  ident: 1919_CR33
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev-immunol-032713-120156
– volume: 464
  start-page: 104
  year: 2010
  ident: 1919_CR13
  publication-title: Nature
  doi: 10.1038/nature08780
– volume: 21
  start-page: 1322
  year: 2024
  ident: 1919_CR43
  publication-title: Cell. Mol. Immunol.
  doi: 10.1038/s41423-024-01221-2
– volume: 69
  start-page: 93
  year: 2017
  ident: 1919_CR22
  publication-title: Pharmacol. Rev.
  doi: 10.1124/pr.116.013078
– volume: 17
  start-page: 5
  year: 2024
  ident: 1919_CR24
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-024-01524-x
– volume: 14
  year: 2023
  ident: 1919_CR5
  publication-title: Nat. Commun.
– volume: 19
  start-page: 23
  year: 2022
  ident: 1919_CR18
  publication-title: Fluids Barriers CNS
  doi: 10.1186/s12987-022-00322-2
SSID ssj0036618
Score 2.4803994
Snippet Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Publisher
StartPage 1283
SubjectTerms 631/250/249
631/250/255
Adenosine monophosphate
Adenosine triphosphate
Adenylate cyclase
Adenylyl Cyclases - deficiency
Adenylyl Cyclases - genetics
Adenylyl Cyclases - metabolism
Agonists
Animals
Binding
Biochemical Engineering
Biochemistry
Bioorganic Chemistry
Catalysis
Cell Biology
Cell culture
Chemical synthesis
Chemistry
Chemistry and Materials Science
Chemistry/Food Science
Clonal deletion
Cyclic AMP
Cytotoxicity
Dimers
Dinucleoside Phosphates - metabolism
Enzymatic activity
Gene deletion
Genes
HEK293 Cells
Humans
Inflammasomes
Inflammasomes - metabolism
Leucine
Mice
Mice, Inbred C57BL
Mice, Knockout
Mitochondrial DNA
Mortality
NLR Family, Pyrin Domain-Containing 3 Protein - metabolism
Nucleotides
Physiology
Potassium
Proteins
TLR9 protein
Toll-Like Receptor 9 - agonists
Toll-Like Receptor 9 - metabolism
Toll-like receptors
Title Eukaryotic ADCY7 catalyzes the production of c-di-AMP to activate the NLRP3 inflammasome
URI https://link.springer.com/article/10.1038/s41589-025-01919-y
https://www.ncbi.nlm.nih.gov/pubmed/40419769
https://www.proquest.com/docview/3234110522
https://www.proquest.com/docview/3212121700
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbK9gAvCDZghYGMhHgpGYntxuljVzZNiFUDFbHxEjmxrVawBK3JpO6v4E_mbOcX6yYxVCmq3FPi-r74vrPvzgi98VPF_JRoL5KKe0yq0EuAR3hSioDxEKyKNvnOx9Pw6Cv7eDo87fV-d6KWyiLZS69uzCv5H61CG-jVZMneQbPNTaEBvoN-4Qoahus_6fig_CEuVrmpuTr-MDnjA7sYs7oyZRtsBpSt5lpRwtSTC298fGLYpslmuASW6UIcP305oSYqC8BxLpbXyhdMbeXPQVoXFqiqNjWBPIvSaOkzoCy7bJcB3Azyfb6Yq8o0msXVhVttPWsR-a2SnMzL7KdadNcgyLCJgCvqEt6mJ9cXzpoiim5mHRKPMVdldk9129xZLfV07BKmK9hFnbkVLCnt2GkgKsGNNsBVfF8CMzHRYKaz4JOOvFVr8Zo4RLsDT6PYCccgHFvheHUPbRJwPGDm3Bwf7u9Pa-tOgc_Y9Mr671SJWHCX9-uP_JvsrHkwa7vvltTMHqGHlTeCxw5aj1FPZVtoe5yJIj9f4bfYxgdbfW-h-5P6bMBtdNoiD1vk4QZ5GCCFW-ThXOMaebjIcY08K2aRh7vIe4JmhwezyZFXndHhpZREhRdoFiZhRPVoyHkgQk2B0lIhg1ArzUeSSCrTKAiJSIJAR4T7KaWJAC-Eq1BI-hRtZHmmdhAWjCc0lWHCdMp8yRNBtQRnm3NNfEGDPhrUYxn_cpVY4tv110e79XDH1Ru7jCkBzgYOBSF99Lr5GYbObJKJTOWlkQnMh_t-Hz1zamoex3wWAH0f9dG7Wm_tzW_vy_O7ib9AD9p3bBdtFBelegnMt0heVWD8A4-FqCE
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Eukaryotic+ADCY7+catalyzes+the+production+of+c-di-AMP+to+activate+the+NLRP3+inflammasome&rft.jtitle=Nature+chemical+biology&rft.au=Liu%2C+Qiannv&rft.au=Tang%2C+Zhiheng&rft.au=Qian%2C+Yan&rft.au=Wang%2C+Chunlei&rft.date=2025-08-01&rft.pub=Nature+Publishing+Group+US&rft.issn=1552-4450&rft.eissn=1552-4469&rft.volume=21&rft.issue=8&rft.spage=1283&rft.epage=1291&rft_id=info:doi/10.1038%2Fs41589-025-01919-y&rft.externalDocID=10_1038_s41589_025_01919_y
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1552-4450&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1552-4450&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1552-4450&client=summon